ALLIANCES AND COLLABORATIONS (AstraZeneca) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Alliances and Collaborations Statement [Line Items]
Net product sales	$ 3,572	$ 2,770	$ 6,631	$ 5,577
Alliance and other revenues	591	1,119	1,573	2,123
Total revenues	4,163	3,889	8,204	7,700
Provision for restructuring	28	16	40	37
Gain on sale of business	8	(7)	162	252
Deferred income - Cash Flow information			(172)	423
Divestitures and other proceeds			294	3,212
Deferred income	1,606		1,606		$ 1,937
AstraZeneca [Member]
Alliances and Collaborations Statement [Line Items]
Net product sales	10	1	10	161
Alliance and other revenues	54	26	108	45
Total revenues	64	27	118	206
Profit sharing - Cost of products sold		1		77
Payments to/(from) alliance partners - Cost of products sold				(9)
Payments to/(from) alliance partners - Marketing, selling and administrative		4		(7)
Payments to/(from) alliance partners - Advertising and product promotion		(1)		(4)
Payments to/(from) alliance partners - Research and development		(2)		(9)
Provision for restructuring				(2)
Royalties	(81)	(90)	(162)	(138)
Transitional services	(2)	(34)	(5)	(65)
Gain on sale of business	1	12	(4)	(247)
Deferred income - Cash Flow information	8	14	9	289
Divestitures and other proceeds	86	152	98	3,207
AstraZeneca [Member] | Amortization Income Expense [Member]
Alliances and Collaborations Statement [Line Items]
Amortization of deferred income	(25)	$ (21)	(49)	$ (34)
AstraZeneca [Member] | Assets Not Yet Transferred to Alliance Partner [Member]
Alliances and Collaborations Statement [Line Items]
Deferred income	185		185		176
AstraZeneca [Member] | Services Not Yet Performed For Alliance Partner [Member]
Alliances and Collaborations Statement [Line Items]
Deferred income	$ 187		$ 187		$ 226